Dobbs Randy E. sold (to issuer) $37K of VMD

Dobbs Randy E. sold (to issuer) 4,191 shares of VIEMED HEALTHCARE, INC. (VMD) at $8.94 on 2026-08-19.

Original reporting
SEC EDGAR · Dobbs Randy E.
Published Aug 19, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
high confidence
Mentioned
$VMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

02

Market read

Minor insider sale; unlikely to move the stock price.

03

What to watch

Potential upcoming corporate actions or earnings that may later affect insider behavior.

Relevance 3/10Novelty 4/10Timing: filing today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$VMDNeutralHigh confidence
Context

Director Randy E. Dobbs sold 4,191 shares of Viemed Healthcare for $37,467, reducing his holdings to 142,253 shares.

Expected impact

Minimal price movement expected.

Evidence & confidence

The transaction size is small relative to float and typical insider activity, and no broader catalyst is present.

Market effects

None; the sale does not affect the healthcare sector broadly.

None; limited to Viemed Healthcare shareholders.

None

Counterpoint

If the director is reducing exposure, it could signal concerns, but the amount is too small to infer material risk.

Key entities

  • Viemed Healthcare, Inc.

    US-listed healthcare company (ticker VMD).

  • Randy E. Dobbs

    Director of Viemed Healthcare.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions